j&j preparing to switch to early ad patients

http://www.reuters.com/article/2013/02/13/us-alzheimers-johnsonjohnson-idUSBRE91C0SX20130213
[Reuters) - A little over a year ago, Dr. Husseini Manji, global head of neuroscience drug development at Johnson & Johnson, predicted that brain researchers were on the cusp of a golden age.

That was before J&J's highly anticipated Alzheimer's drug, bapineuzumab, failed to improve memory and thinking skills in closely watched clinical trials of people with mild to moderate forms of the disease.

Had it worked, the drug would have been the first to alter the course of Alzheimer's, a fatal brain-wasting disease that affects 36 million people worldwide. It also would have meant billions of dollars in annual sales.]
[Like its rivals, J&J is preparing to pivot from testing drugs in people who already have dementia to early-stage patients, when drugs may have a better shot at working.]

Prana´s PBT2, the drug which has demonstrated efficacy against diagnosed Alzheimer´s patients in just 12 weeks, continues further trials against diagnosed Alzheimer´s patients, and prodromal patients.